12 research outputs found
American Diabetes Association proposes to use HbA1c level for diagnosis of diabetes mellitus
ΠΠΌΠ΅ΡΠΈΠΊΠ°Π½ΡΠΊΠ°Ρ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ (ADA), Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ ΠΎΠ±Π½ΠΎΠ²Π»ΡΡΡΠ°Ρ ΡΠ²ΠΎΠΈ ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ, Π² ΠΈΡ
ΠΏΠ΅ΡΠ΅ΡΠΌΠΎΡΡΠ΅ 2010 Π³. Π±ΡΠ΄Π΅Ρ ΠΏΡΠ΅Π΄Π»Π°Π³Π°ΡΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ. ΠΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π±ΡΠ΄ΡΡ ΠΊΠ°ΡΠ°ΡΡΡΡ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΡΠ°Π·Π΄Π΅Π»ΠΎΠ², ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π°ΡΡΠΎΠ½ΡΡ ΡΠ°Π·Π΄Π΅Π» Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ°?. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΡΠ΅ΠΊΡΠΈΡ, ΡΠ°Π½Π΅Π΅ Π½Π°Π·ΡΠ²Π°Π²ΡΠ°ΡΡΡ ?ΠΡΠ΅Π΄ΠΈΠ°Π±Π΅Ρ?, Π±ΡΠ΄Π΅Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π° ΠΈ ΠΏΠ΅ΡΠ΅ΠΈΠΌΠ΅Π½ΠΎΠ²Π°Π½Π° Π² ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° Π΄ΠΈΠ°Π±Π΅ΡΠ°?
The 5th International Conference on Advanced Technologies Treatments for Diabetes (ATTD 2012),2012 February 8-11, Barcelona (Spain)
ΠΡΡΠ°Ρ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½Π°Ρ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΡ ATTD (Advanced Technologies & Treatment for Diabetes) ΠΏΡΠΎΡΠ»Π° 8?11 ΡΠ΅Π²ΡΠ°Π»Ρ 2012 Π³ΠΎΠ΄Π° Π² ΠΡΠΏΠ°Π½ΠΈΠΈ (Π³. ΠΠ°ΡΡΠ΅Π»ΠΎΠ½Π°). ΠΠ°Π½Π½ΠΎΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠ΅ ΠΎΡΠ³Π°Π½ΠΈΠ·ΡΠ΅ΡΡΡ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ ΠΏΠΎΠ΄ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎΠΌ ΠΏΡΠΎΡ. Phillip Moshe (Institute for Endocrinology and Diabetes, Israel) ΠΈ Tadej Bottelino (University Children?s Hospital, Slovenia). Π 2012 Π³ΠΎΠ΄Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΡΠ΅Π·ΠΎΠ½Π°Π½Ρ Π² ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Π΅ Π²ΡΠ·Π²Π°Π»ΠΈ ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠΈ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΠΏΠΎΠΌΠΏΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π·Π°ΠΌΠΊΠ½ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΡΠ°?, ΡΠ΅Π»Π΅ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΈ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ. Π’ΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎ Π±ΡΠ» ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΡΠ΅ΡΠ΅Π΄Π½ΠΎΠΉ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠΉ Π²ΡΠΏΡΡΠΊ ?ATTD Yearbook 2011? ? ΠΊΠΎΠ»Π»Π΅ΠΊΡΠΈΡ ΡΠ΅ΠΏΡΠΈΠ½ΡΠΎΠ² Π»ΡΡΡΠΈΡ
ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
Π·Π° Π³ΠΎΠ΄ ΡΡΠ°ΡΠ΅ΠΉ ΠΏΠΎ Π½ΠΎΠ²ΡΠΌ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠΌ Π² Π΄ΠΈΠ°Π±Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠΌΠΈ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ²
Immunovospalitel'nye markery ateroskleroza u patsientov s narushennoy tolerantnost'yu k glyukoze i sakharnym diabetom 2 tipa
Π¦Π΅Π»Ρ. Π‘ΠΎΠΏΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ
(Π’ΠΠ ) ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π°ΡΡΡΠ΅Π½Π½ΠΎΠΉ ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ Π³Π»ΡΠΊΠΎΠ·Π΅ (ΠΠ’Π) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π³ΡΡΠΏΠΏΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ’Π (n=14, Π³ΡΡΠΏΠΏΠ° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Π±Π΅Π· ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (n=12), Π³ΡΡΠΏΠΏΠ° Π‘Π 2 Ρ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ (ΠΠΠ‘, ΠΈΠ½ΡΡΠ»ΡΡ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅, ΠΎΠ±Π»ΠΈΡΠ΅ΡΠΈΡΡΡΡΠΈΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π½ΠΈΠΆΠ½ΠΈΡ
ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΡΡΠ΅ΠΉ) (n=32) ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ Π³ΡΡΠΏΠΏΠ° (n= 10) Π±Π΅Π· Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π‘Π‘Π, ΠΠ ΠΈ Π‘Π 2. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ (1Π‘ΠΠ-1 ΠΈ VCAM) ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π°Π±ΠΎΡΠΎΠ² EL1SA; ΡΡΠΎΠ²Π΅Π½Ρ hs-Π‘Π Π ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΡΠ²Π΅ΡΠ΄ΠΎΡΠ°Π·Π½ΡΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ. ΠΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ Π²Π΅Π»ΠΈΡΠΈΠ½Ρ Π’ΠΠ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π£Π Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ Π² Π΄ΠΈΡΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΠ°Π½ΡΠΈΠΌΠ΅ΡΡΠ΅ ΠΎΠ±ΡΠ΅ΠΉ ΡΠΎΠ½Π½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ (ΠΠ‘Π) ΡΠ»Π΅Π²Π° Ρ ΡΠ°ΡΡΠ΅ΡΠΎΠΌ ΡΡΠ΅Π΄Π½Π΅Π³ΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π’ΠΠ, ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠΉ Π² ΡΡΠ΅Ρ
ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΡΡ
ΡΠΈΠΊΠ»Π°Ρ
. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ’Π ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Π±Π΅Π· ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΡΠ΅Π΄Π½Ρ Ρ Π²Π΅Π»ΠΈΡΠΈΠ½Π° Π’ΠΠ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½Π΅ ΡΠ°Π·Π»ΠΈΡΠ°Π»Π°ΡΡ, Π½ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΏΡΠ΅Π²ΡΡΠ°Π»Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅. ΠΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ Π’ΠΠ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Ρ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ, ΡΡΠΎ Π±ΡΠ»ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ Ρ ΠΠ’Π ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Π±Π΅Π· ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ. ΠΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ ICAM-1 ΠΈ VCAM- 1 Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΏΡΠ΅Π²ΡΡΠ°Π»ΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΡ (Π² 1.5 ΡΠ°Π·Π° Π² Π³ΡΡΠΏΠΏΠ°Ρ
ΠΠ’Π ΠΈ Π½Π΅ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΠΎΠ³ΠΎ Π‘Π 2 ΠΈ ΠΏΡΠΈΠ±Π»ΠΈΠ·ΠΈΡΠ΅Π»ΡΠ½ΠΎ Π² 2 ΡΠ°Π·Π° ? Π² Π³ΡΡΠΏΠΏΠ΅ Π‘Π 2 Ρ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ). ΠΡΡΠΏΠΏΠ° Π‘Π 2 Ρ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π»Π°Ρ Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΠΌΠΈ Π·Π½Π°ΡΠ΅Π½ΠΈΡΠΌΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ ICAM- 1 ΠΈ VCAM-1. ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ Π’ΠΠ Π½Π΅ Π±ΡΠ»ΠΎ. ΠΡΠ²ΠΎΠ΄Ρ. ΠΠ΅Π»ΠΈΡΠΈΠ½Π° Π’ΠΠ Π½Π° ΡΡΠ°Π΄ΠΈΠΈ ΠΠ’Π ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠ° Ρ Π’ΠΠ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Π±Π΅Π· ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ , ΡΡΠΎ ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π½Π°Π»ΠΈΡΠΈΠΈ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ΅Π½ΠΊΠΈ ΡΠΆΠ΅ Π½Π° ΡΠ°Π½Π½ΠΈΡ
ΡΡΠ°Π΄ΠΈΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ°. ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ Π²Π΅Π»ΠΈΡΠΈΠ½Ρ Π’ΠΠ Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΠ ΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ ΡΠ°ΠΊΠΎΠ²ΠΎΠΉ Ρ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° (HbAlc ) ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ , ΡΡΠΎ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠ΅ΡΡΠΎΠ½ΠΈΡ Π²Π½ΠΎΡΠΈΡ Π±ΠΎΠ»ΡΡΠΈΠΉ Π²ΠΊΠ»Π°Π΄ Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΏΡΠΈ Π‘Π 2, ΡΠ΅ΠΌ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ. ΠΡΡΠΎΠΊΠ°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π° (hs-Π‘Π Π, Π°Π΄Π³Π΅Π·ΠΈΠ²Π½ΡΡ
ΠΌΠΎΠ»Π΅ΠΊΡΠ» VCAM1 ΠΈ ICAM1) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π 2 Ρ ΠΌΠ°ΠΊΡΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π°ΡΠ΅ΡΠΎΡΠΊΠ»Π΅ΡΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ° . ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎ Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π’ΠΠ , hs-Π‘Π Π, ΠΌΠΎΠ»Π΅ΠΊΡΠ» Π°Π΄Π³Π΅Π·ΠΈΠΈ ΠΏΡΠΈ Π‘Π 2 ΡΠ»Π΅Π΄ΡΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π΄Π»Ρ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³ΡΡΠΏΠΏ ΠΎΡΠ΅Π½Ρ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ°
Prevalence of renal lesions in patients with type 1 and 2 diabetes mellitus in the Russian Federation
Aim.
To study the prevalence of renal lesions in adult patients with type 1 and 2 diabetes mellitus in the Russian Federation.
Materials and methods.
A total of 7174 patients with DM1 and DM2 were examined in 20 regions of the Russian Federation for blood HbA1c creatinine,urea, and cholesterol levels, albumin excretion in a single urine sample, AP, and eye fundus condition. Albumin concentration from 20 to 200mg/l was regarded as microalbuminuria (MAU) that above 200 mg/l as proteinuria (PU). The glomerular filtration rate (GFR) was calculated fromCockroft-Gault formula. Statistica-6 program was used for statistical treatment of the results of the study. They are represented as median, 25th and75th percentile values (Me [25%;75%]). Differences between all parameters is considered significant at
Federal targeted programme 'Prevention and Management of Socially Significant Diseases (2007-2012)': results of the 'Diabetes mellitus' sub-programme
During 2007-2012 years the ?Diabetes mellitus? sub-programme reached the performance targets with the following results.
Development of the State Diabetes Register covering all regions of the Russian Federation. The Register facilitates the continuous evaluation and planning of diabetes care in this country, analysis of epidemiological dynamics (including incidence and mortality in diabetes population) and human resources management.
Alteration of the demographics of the national diabetes population, specifically:
- an increase in life expectancy among T1DM patients: up to 56.7 years (+3.8 years) in males and up to 60.8 years (+4.1 years) in females; an increase in life expectancy among T2DM patients: up to 72.4 years (+3.2 years) in males and up to 74.5 years (+2.9 years) in females;
- a reduction in mortality of diabetes patients for 28.4%;Β
Introduction of novel technologies for diagnostics, prevention and management of DM and its complications, that, in turn, allowed to:
- decrease the incidence of diabetic nephropathy for 16.1% and extend the pre-dialysis period;
- decrease the incidence of diabetic retinopathy for 11.4% and preserve vision in 86-91% patients who still develop this complication;
- decrease the frequency of upper- and lower-level amputations for 24% and 28%, respectively, and to reduce the ulcer healing times 2.5 to 3-fold;
Introduction of safe and highly efficient human recombinant insulin and its analogues in the regions of the Russian Federation, along with modern methods of insulin administration and outpatient blood glucose monitoring.
Establishment of diabetes educational centres (more than 1100 in the regions of the Russian Federation) that resulted in substantial reduction of number and frequency of diabetes-associated hospital admissions.
The sub-programme is estimated to have saved 6 727 596.9 thousand Russian rubles of the budgetary funds due to decrease in the incidence of microvascular complications. A total of 360 papers (including 35 in international medical journals), as well as 81 clinical guidance manuals and 23 monographs were published during the course of this sub-programme
Russian Association of Endocrinologists expert consensus document on initiation and intensification of antyhyperglycaemic therapyin type 2 diabetes mellitus
Current consensus proposes a differentiated algorithm of initiation and intensification of antihyperglycaemic therapy in treatment patients withtype 2 diabetes mellitus. Patient-centered approach is considered a priority at any stage of diabetes care, as it ensures efficiency and safety of treatment.This document formulates guidelines for setting adequate therapeutic goals depending on vascular complications, age, life expectancy and riskof hypoglycemic events. Therapeutic options are stratified with regard to initial HbA1c level. This Algorithm considers all classes of antidiabetic medicationsregistered in Russian Federation, rational and irrational combinations of drugs as well as contraindications
Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015)
The current update of the consensus algorithm of initiation and intensification of the antihyperglicemic therapy in treatment of the patients with type 2 diabetes mellitus (2015) is based on the preliminary document issued by the Russian Association of the Endocrinologists in 2011.
The update was needed due to new data on the safety of the traditional therapeutic options, availability of the new class of the antidiabetic medications, and necessity to add chapter about initiation and intensification of the insulin therapy.
The patient-centered approach remains the absolute priority at any stage of diabetes care as it ensures the efficacy and safety of antihyperglycaemic treatment
Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensificationof hypoglycemic therapy for type 2 diabetes mellitus
Π‘ ΡΡΠ΅ΡΠΎΠΌ ΠΌΠ°ΡΡΡΠ°Π±Π° ΡΠ°Π·Π²ΠΈΠ²Π°ΡΡΠ΅ΠΉΡΡ ΡΠΏΠΈΠ΄Π΅ΠΌΠΈΠΈ Π‘Π ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΎΡΡΡΠ΅ΠΉΡΠ°Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π»Π³ΠΎΡΠΈΡΠΌΠ° ΡΠ°Ρ
Π°ΡΠΎΡΠ½ΠΈΠΆΠ°ΡΡΠ΅Π³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ΅Π³ΠΎ Π΄ΠΎΡΡΠΈΡΡ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅Π΄ΠΈΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΡΠΆΠ΅Π»ΡΡ
ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΡΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠΈ ΡΡΠΎΠΌ ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠΎΠΌ Π² Π²ΡΠ±ΠΎΡΠ΅ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ΅Π΄ΡΡΠ² Π΄ΠΎΠ»ΠΆΠ½Π° ΡΡΠ°ΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ°Ρ
Π°ΡΠΎΡΠ½ΠΈΠΆΠ°ΡΡΠ΅Π³ΠΎ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΏΡΠΈ ΠΈΡ
Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (ΠΊΠ°ΠΊ ΠΊΡΠ°Ρ- ΠΊΠΎΡΡΠΎΡΠ½ΠΎΠΉ, ΡΠ°ΠΊ ΠΈ ΠΎΡΠ΄Π°Π»Π΅Π½Π½ΠΎΠΉ)
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition)
We are glad to present theΒ 7th Edition of Standards of Diabetes Care.
These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation.
The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), American Diabetes Association (ADA, 2012, 2015), American Association of Clinical Endocrinologists (AACE, 2013), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2014) and Russian Association of Endocrinologists (RAE, 2011, 2012).
Current edition of the ?Standards? also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals.
Latest data indicates that prevalence of DM increased during the last decade more than two-fold, reaching some 387 million patients by the end of 2014. According to the current estimation by the International Diabetes Federation, 592 million patients will be suffering from DM by 2035. These observations resulted in the UN Resolution 61/225 passed on 20.12.2006 that encouraged all Member States "to develop national policies for the prevention, treatment and care of diabetes".
Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian State Diabetes Register, there are at least 4.1 million patients with DM in this country. However, the epidemiological survey conducted by the Federal Endocrinology Research Centre during 2002-2010 suggests that actual prevalence is 3 to 4 times greater than the officially recognized and, by this estimate, amounts to 9-10 million persons, comprising 7% of the national population.
Severe consequences of the global pandemics of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death.
Current edition of the "Standards" emphasizes the patient-oriented approach in making decisions on therapeutic goals, such as levels of glycaemia and blood pressure. It also features updated guidelines on the management of vascular complications.
This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discussions held at national meetings and forums. These guidelines are intended for endocrinologists and diabetologists, primary care physicians, cardiologists and other medical professionals involved in prevention and treatment of diabetes mellitus
Diabetes mellitus and chronic kidney disease: achievements, unresolved problems, and prospects for therapy
The dramatic increase in the number of patients with diabetes mellitus (DM) and chronic renal disease (CRD) in the recent years emphasizes the closeassociation between the two conditions and the leading role of DM in the development of renal pathology. Diabetology and nephrology are highly costlybranches of public health, and the burden of substitution renal therapy in DM patients continues to grow. The necessity of a renoprotection programat the early stages of DM for the prevention or delay of terminal renal insufficiency becomes increasingly clear. Such program should be based on theconceptual model of the evolvement of diabetic nephropathy as a consequence of combined action of metabolic and hemodynamic factors modulatedby genetic ones